Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TARGINIQ vs ATROPINE AND DEMEROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TARGINIQ combines naloxegol, a peripherally acting mu-opioid receptor antagonist (PAMORA), with oxycodone, a full mu-opioid receptor agonist. Naloxegol reduces opioid-induced constipation by blocking opioid effects in the gastrointestinal tract without affecting central analgesia.
Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.
FDA-approved: Management of severe chronic pain requiring daily around-the-clock opioid treatment, in patients who have responded to and tolerated oxycodone and require treatment for opioid-induced constipation.,Off-label: Not specified
Preanesthetic medication to reduce secretions and prevent bradycardia,Management of moderate to severe pain (as an opioid analgesic),Off-label: treatment of opioid-induced constipation (meperidine component)
1 tablet orally every 12 hours, each tablet containing oxycodone hydrochloride 10 mg and naloxone hydrochloride 5 mg (as naloxone hydrochloride dihydrate). Dose may be titrated based on analgesic requirements; maximum daily dose: oxycodone 80 mg and naloxone 40 mg.
Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.
Oxycodone terminal half-life is 3.5-4.0 hours; naloxone half-life is 1-1.5 hours. The prolonged-release formulation yields a longer apparent half-life, supporting twice-daily dosing.
Atropine: 2-4 hours (terminal half-life). Demerol: 2.5-4 hours; normeperidine metabolite half-life 15-30 hours (accumulates in renal impairment).
Oxycodone: primarily hepatic via CYP3A4 and CYP2D6. Naloxegol: primarily hepatic via CYP3A4.
Meperidine is primarily metabolized in the liver via hydrolysis to meperidinic acid and via N-demethylation to normeperidine (active metabolite), involving CYP3A4 and CYP2B6. Atropine is metabolized in the liver via hydrolysis and glucuronidation; approximately 50% is excreted unchanged in urine.
Oxycodone is primarily excreted renally as noroxycodone and free oxycodone; naloxone undergoes extensive hepatic metabolism and is excreted renally as naloxone-3-glucuronide. For TARGINIQ, approximately 87% of the dose is eliminated in urine: 19% as unchanged oxycodone, 1% as unchanged naloxone, and the remainder as metabolites. Fecal excretion accounts for ~10%.
Atropine: approximately 50% excreted unchanged in urine, remainder as metabolites (biliary and renal). Demerol (meperidine): primarily hepatic metabolism; <5% excreted unchanged in urine; metabolites (including normeperidine) excreted renally.
Oxycodone: 45% bound primarily to albumin. Naloxone: approximately 40% bound predominantly to albumin.
Atropine: ~44% bound to albumin and alpha-1 acid glycoprotein. Demerol: ~60% bound to albumin and alpha-1 acid glycoprotein.
Oxycodone: Vd 2.6 L/kg, indicating extensive tissue distribution. Naloxone: Vd 2.1 L/kg.
Atropine: 1-3 L/kg (large, extensive tissue distribution). Demerol: 3-5 L/kg (large, distributes widely including CNS).
Oral bioavailability of oxycodone: 60-87% (first-pass metabolism). Naloxone oral bioavailability: <2% due to extensive first-pass hepatic metabolism, allowing local gastrointestinal effect without significant systemic opioid antagonism.
Atropine: oral ~10-25% (extensive first-pass metabolism). Demerol: oral ~50-60% (significant first-pass metabolism). IM/IV 100%.
For GFR <60 m L/min: initiate at 50% of usual dose and titrate cautiously. For GFR <30 m L/min: consider alternative therapy; if used, reduce starting dose by 50% and monitor closely. Not recommended in end-stage renal disease (GFR <15 m L/min).
Meperidine: GFR 10-50 m L/min: administer 75% of normal dose; GFR <10 m L/min: administer 50% of normal dose and avoid due to normeperidine accumulation. Atropine: no adjustment required.
Child-Pugh Class A: no adjustment required. Child-Pugh Class B: initiate at 50% of usual dose and titrate cautiously. Child-Pugh Class C: contraindicated due to risk of naloxone accumulation and CNS effects.
Meperidine: Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce by 50%; Child-Pugh C: contraindicated. Atropine: caution in severe hepatic impairment.
Not recommended for use in pediatric patients (≤18 years) due to lack of safety and efficacy data.
Atropine 0.01 mg/kg (max 0.4 mg) and meperidine 1-2 mg/kg (max 100 mg) intramuscularly 30-60 minutes before procedure.
Initiate at the lower end of the dosing range (e.g., 1 tablet every 12 hours) and titrate cautiously. Monitor for signs of CNS depression, constipation, and respiratory depression. Consider baseline renal and hepatic function for dose adjustments.
Reduce meperidine dose by 50% and avoid in elderly due to risk of seizures and delirium; use alternative opioids. Atropine dose unchanged but monitor for anticholinergic effects.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of even one dose of TARGINIQ, especially by children, can cause fatal respiratory depression; neonatal opioid withdrawal syndrome; opioid-induced hyperalgesia and allodynia; concomitant use with CYP3A4 inhibitors or discontinuation of CYP3A4 inducers may increase naloxegol exposure and risk of adverse reactions.
Meperidine has a boxed warning for risk of respiratory depression, especially in elderly, cachectic, or debilitated patients, and when used with CNS depressants. Also, risk of serotonin syndrome when co-administered with serotonergic drugs, and risk of abuse, addiction, and diversion.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion,Neonatal opioid withdrawal syndrome,Opioid-induced hyperalgesia and allodynia,CYP3A4 inhibitor/inducer interactions with naloxegol,Gastrointestinal obstruction: naloxegol is contraindicated in patients with known or suspected gastrointestinal obstruction,Risk of severe opioid withdrawal symptoms with abrupt discontinuation or naloxegol dose increase
Respiratory depression, hypotension, bradycardia, urinary retention, constipation, serotonin syndrome, seizures (normeperidine accumulation), decreased GI motility, drug dependence, and tolerance. Use caution in elderly, renal impairment, hepatic impairment, respiratory disorders, prostatic hyperplasia, glaucoma, and with concurrent CNS depressants.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction,Concurrent use of strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) with naloxegol,Hypersensitivity to oxycodone, naloxegol, or any component of the formulation
Hypersensitivity to atropine or meperidine; severe asthma or COPD; acute respiratory depression; paralytic ileus; known or suspected gastrointestinal obstruction; patients receiving MAOIs (within 14 days); myasthenia gravis (relative for atropine); increased intraocular pressure (glaucoma); severe renal impairment (normeperidine accumulation).
Take on an empty stomach at least 1 hour before or 2 hours after a meal. Avoid grapefruit juice and other CYP3A4 inhibitors in food, as they may increase naloxegol levels.
Avoid alcohol. Meperidine may interact with foods containing tyramine (aged cheeses, cured meats) in patients on MAOIs; otherwise no significant food interactions.
Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS). First trimester: Limited data; animal studies show increased risk of neural tube defects at high doses. Second and third trimesters: Chronic use may lead to fetal dependence and withdrawal at birth.
Atropine: FDA Pregnancy Category C. Crosses placenta; may cause fetal tachycardia. Demerol (meperidine): FDA Pregnancy Category C. First trimester: limited human data; animal studies show no teratogenicity. Second trimester: no specific risks. Third trimester: use near term may cause neonatal respiratory depression, decreased Apgar scores, and withdrawal symptoms. Chronic use may lead to neonatal opioid withdrawal syndrome (NOWS).
Oxycodone and naloxone are excreted in breast milk. Oxycodone M/P ratio approximately 3.2. Use with caution; monitor infant for respiratory depression and sedation. Consider risk of infant opioid exposure.
Atropine: Excreted in breast milk in small amounts; may inhibit lactation. M/P ratio not established. Use with caution; monitor infant for anticholinergic effects (tachycardia, dry mouth). Demerol: Excreted in breast milk; relative infant dose (RID) ~0.5-0.8% of maternal weight-adjusted dose. M/P ratio 1.0-1.6. Limited data; avoid in breastfeeding due to potential neonatal sedation and respiratory depression. American Academy of Pediatrics considers meperidine compatible but caution advised.
Pregnancy may increase clearance of oxycodone; dose adjustments may be required. However, no specific guidelines. Use lowest effective dose; avoid prolonged use. Taper if discontinuing to prevent withdrawal.
Atropine: No specific dose adjustments recommended; increased volume of distribution may require higher doses for effect. Demerol: Increased clearance and volume of distribution in pregnancy; standard doses may be less effective. Avoid use during labor due to risk of neonatal respiratory depression; if necessary, use lowest effective dose and monitor neonate. No specific dose reduction recommended, but caution with repeated doses.
TARGINIQ (naloxegol) is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for opioid-induced constipation (OIC) in adults with chronic non-cancer pain. It does not cross the blood-brain barrier, so it does not reverse central analgesia or precipitate opioid withdrawal. Contraindicated in patients with known or suspected gastrointestinal obstruction. Administer on an empty stomach at least 1 hour before or 2 hours after a meal. Avoid use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) as they increase naloxegol exposure. Dose adjustments needed for moderate or severe hepatic impairment.
Atropine and Demerol (meperidine) combination is used for pre-anesthetic medication to reduce secretions and produce sedation. Monitor for CNS depression, respiratory depression, and anticholinergic effects (tachycardia, dry mouth, urinary retention). Use cautiously in elderly, patients with COPD, asthma, or prostatic hyperplasia. Avoid in patients with MAOIs due to risk of serotonin syndrome.
Take TARGINIQ on an empty stomach, at least 1 hour before or 2 hours after eating.,Do not crush or chew the tablet; swallow it whole with water.,If you miss a dose, skip it and take the next dose at the regular time. Do not take two doses at once.,Common side effects include abdominal pain, diarrhea, nausea, gas, and headache. Call your doctor if you have severe or persistent symptoms.,Seek immediate medical attention if you have severe stomach pain, vomiting, or if you are unable to pass stool (possible bowel obstruction).,Inform your doctor about all medications you take, especially strong CYP3A4 inhibitors like certain antibiotics or antifungals.,TARGINIQ does not affect the pain relief from your opioid medication; continue taking your pain medicine as prescribed.,Store at room temperature away from moisture and heat.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until effects are known.,Avoid alcohol and other CNS depressants while taking this medication.,Report difficulty urinating, fast heartbeat, or severe constipation to your healthcare provider.,Do not take more than prescribed; risk of dependence with long-term use.,Keep out of reach of children; may cause serious breathing problems if accidentally taken.
No interactions on record
"Rivastigmine, a reversible carbamate acetylcholinesterase inhibitor, increases synaptic acetylcholine levels, enhancing cholinergic transmission. Atropine, a competitive antagonist of muscarinic acetylcholine receptors, blocks the effects of acetylcholine at these receptors, leading to reduced parasympathetic activity. When used together, atropine can diminish the therapeutic efficacy of rivastigmine by pharmacodynamically antagonizing its cholinergic effects, particularly in the central nervous system and peripheral muscarinic receptors, potentially worsening cognitive function in Alzheimer's disease patients."
"Umeclidinium, a long-acting muscarinic antagonist (LAMA), and atropine, a non-selective muscarinic antagonist, both block the action of acetylcholine at muscarinic receptors in the parasympathetic nervous system. Their co-administration leads to additive anticholinergic effects, resulting in an increased risk of peripheral anticholinergic adverse effects such as dry mouth, blurred vision, constipation, urinary retention, and tachycardia, as well as central nervous system effects like confusion or delirium, especially in elderly patients. Clinically, this combination may also exacerbate conditions such as angle-closure glaucoma or paralytic ileus."
"Concurrent use of atropine and gallamine triethiodide results in additive antagonism at muscarinic acetylcholine receptors, leading to enhanced blockade of parasympathetic effects and increased risk of tachycardia, hypertension, and delirium. Atropine, a competitive antagonist of muscarinic receptors, counteracts the vagolytic effects of gallamine, a nondepolarizing neuromuscular blocker that also exhibits weak vagolytic activity. This pharmacodynamic interaction can cause severe sinus tachycardia, hypertension, and central anticholinergic syndrome, especially in elderly patients or those with cardiovascular disease."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TARGINIQ vs ATROPINE AND DEMEROL, answered by our medical review team.
TARGINIQ is a Opioid Analgesic Combination that works by TARGINIQ combines naloxegol, a peripherally acting mu-opioid receptor antagonist (PAMORA), with oxycodone, a full mu-opioid receptor agonist. Naloxegol reduces opioid-induced constipation by blocking opioid effects in the gastrointestinal tract without affecting central analgesia.. ATROPINE AND DEMEROL is a Opioid Analgesic Combination that works by Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TARGINIQ and ATROPINE AND DEMEROL depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TARGINIQ is: 1 tablet orally every 12 hours, each tablet containing oxycodone hydrochloride 10 mg and naloxone hydrochloride 5 mg (as naloxone hydrochloride dihydrate). Dose may be titrated based on analgesic requirements; maximum daily dose: oxycodone 80 mg and naloxone 40 mg.. The standard adult dose of ATROPINE AND DEMEROL is: Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TARGINIQ and ATROPINE AND DEMEROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TARGINIQ is classified as Category C. Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS). First trimester: Limited data; animal studies show increased risk of neural tube. ATROPINE AND DEMEROL is classified as Category C. Atropine: FDA Pregnancy Category C. Crosses placenta; may cause fetal tachycardia. Demerol (meperidine): FDA Pregnancy Category C. First trimester: limited human data; animal studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.